Literature DB >> 17266646

Stability of synthetic exendin-4 in human plasma in vitro.

Jie Chen1, Ling Yu, Liping Wang, Xuexun Fang, Li Li, Wei Li.   

Abstract

Sites of exendin-4 that that are relatively susceptible to degradation in plasma were identified with the aim of providing information for designing new exendin-4 analogues. The stability of exendin-4 in human plasma was evaluated in vitro. The results showed that the peptide was slowly degraded with a half-life of 9.57 h and the principal cleavage sites are between Thr5 and Phe6, Phe6 and Thr7, and Thr7 and Ser8 of the N-terminus region of exendin-4.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266646     DOI: 10.2174/092986607779117272

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  4 in total

1.  18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.

Authors:  Dale O Kiesewetter; Haokao Gao; Ying Ma; Gang Niu; Qimeng Quan; Ning Guo; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-15       Impact factor: 9.236

2.  In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.

Authors:  Sha Liao; Yuanjun Liang; Zhiwei Zhang; Jinglai Li; Juan Wang; Xiaoying Wang; Guifang Dou; Zhenqing Zhang; Keliang Liu
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

3.  A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia.

Authors:  Joseph Chabenne; Maria Dimarchi Chabenne; Yan Zhao; Jay Levy; David Smiley; Vasily Gelfanov; Richard Dimarchi
Journal:  Mol Metab       Date:  2014-01-22       Impact factor: 7.422

4.  The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.

Authors:  Jing Lv; Yu Pan; Xiao Li; Dengfeng Cheng; Shuai Liu; Hongcheng Shi; Yifan Zhang
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.